Anti-hyperglycemic activity of zinc plus cyclo (his-pro) in genetically diabetic Goto-Kakizaki and aged rats

Exp Biol Med (Maywood). 2003 Dec;228(11):1338-45. doi: 10.1177/153537020322801112.

Abstract

We previously reported that treatment of streptozotocin-induced diabetic rats with zinc plus cyclo (his-pro) (CHP) decreased fed blood glucose levels and water intake. The present study was conducted to examine the dose-dependent, acute, and chronic treatment effects of CHP on oral glucose tolerance (OGT), fed blood glucose levels, water intake, and plasma insulin levels in young and aged Sprague-Dawley (S-D) rats, nondiabetic Wistar rats, and genetically diabetic Goto-Kakizaki (G-K) rats. Acute gastric gavage of 10 mg zinc plus 1.0 mg CHP/kg body weight significantly improved OGT in 4- and 13-month-old nondiabetic S-D rats and in 2-month-old diabetic G-K rats. Young S-D and G-K rats returned to pretreatment OGT values 1 week after acute gavage of zinc plus CHP (ZC), but improved OGT values persisted for at least 1 week after gavage in aged S-D rats. OGT values and fed blood glucose decreased to the greatest extent among other treatments when G-K rats were given free access to drinking water containing 1.0 to 1.5 mg CHP/L plus 10 mg zinc/L for 2 weeks. Although food and water intake showed a tendency to decrease, no statistically significant differences were observed in young G-K rats. Plasma insulin levels and blood glucose levels in both normal and diabetic G-K rats decreased with 2-week treatment with ZC. To test the direct effects of ZC on muscle tissue, we observed the effect of various doses of ZC on normal and G-K rat muscle slices. The optimal level of CHP alone for maximal muscle glucose uptake in muscle slices from normal rats was 10 microg/mL and 5.0 microg/mL in G-K rats, and ZC stimulated glucose uptake. However, no statistically significant difference was demonstrated between normal and G-K rat tissues in this study. These results indicate that oral intake of an optimal dose of ZC stimulates blood glucose metabolism, probably by stimulating muscle glucose utilization.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aging / blood
  • Animals
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics*
  • Drinking / drug effects
  • Female
  • Glucose / metabolism
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacology*
  • In Vitro Techniques
  • Insulin / blood
  • Male
  • Muscles / drug effects
  • Muscles / metabolism
  • Peptides, Cyclic / administration & dosage
  • Peptides, Cyclic / pharmacology*
  • Piperazines / administration & dosage
  • Piperazines / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Rats, Sprague-Dawley
  • Rats, Wistar
  • Zinc / administration & dosage
  • Zinc / pharmacology*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Peptides, Cyclic
  • Piperazines
  • Glucose
  • Zinc
  • histidyl-proline diketopiperazine